



## **CRISPR Therapeutics to Participate in Four Upcoming Investor Conferences**

February 21, 2018

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 21, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that members of its senior management team are scheduled to present at four upcoming Investor Conferences.

### **2018 RBC Capital Markets Global Healthcare Conference**

Date: Thursday, February 22, 2018

Presentation: 8:00-8:25 AM ET

Webcast available under Investor Relations tab at [CRISPRTx.com](http://CRISPRTx.com)

### **Barclays Global Healthcare Conference**

Date: Tuesday, March 13, 2018

Presentation: 3:20-3:45 PM ET

### **Guggenheim Conference on Disruptive Technologies in Immuno-Oncology**

Date: March 27<sup>th</sup>, 2018

### **17th Annual Needham Healthcare Conference**

Date: March 28th, 2018

Presentation: 3:30 PM ET

### **About CRISPR Therapeutics**

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit <http://www.crisprtx.com>.

### **MEDIA CONTACT:**

Jennifer Paganelli

WCG on behalf of CRISPR

+1 347-658-8290 [jpaganelli@wgcworld.com](mailto:jpaganelli@wgcworld.com)

### **INVESTOR CONTACT:**

Chris Erdman

+1 617.307.7227 [chris.erdman@crisprtx.com](mailto:chris.erdman@crisprtx.com)

Chris Brinzey

Westwicke Partners for CRISPR

+1 339-970-2843 [chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)



CRISPR Therapeutics AG